Salvador-Martín, SaraKaczmarczyk, BartoszÁlvarez, RebecaNavas-López, Víctor ManuelGallego-Fernández, CarmenMoreno-Álvarez, AnaMerino Bohórquez, VicenteLópez-Fernández, Luís A.2021-02-102021-02-102021-01-08Salvador-Martín, S., Kaczmarczyk, B., Álvarez, R., Navas-López, V.M., Gallego-Fernández, C., Moreno-Álvarez, A.,...,Merino-Bohórquez, V. (2021). Whole transcription profile of responders to anti-tnf drugs in pediatric inflammatory bowel disease. Pharmaceutics, 13 (1), 1-17.1999-4923https://hdl.handle.net/11441/104820Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged < 18 years who started treatment with infliximab or adalimumab (29 responders and nine non-responders). Whole gene expression profiles from total RNA isolated from whole blood samples of six responders and six non-responders taken before administration of the biologic and after two weeks of therapy were analyzed using next-generation RNA sequencing. The expression of six selected genes was measured for purposes of validation in all of the 38 patients recruited using qPCR. Results: Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or <−0.6 and p value < 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21, and 1.08, respectively, p value < 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBDapplication/pdf17engAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/BiomarkerGene expressionInfliximabAdalimumabUlcerative colitisCrohn diseaseInflammatory bowel diseaseinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccesshttps://doi.org/10.3390/pharmaceutics13010077